iSERA Lifesciences Q2 FY27 Results (BSE: 534920)
Signal: Loss narrowed
The read
The immediate inflection is a narrower ₹13.11 lakh net loss versus ₹33.62 lakh QoQ, but the underlying trajectory remains weak because operating revenue is not disclosed, ₹7.88 lakh of interest income is the sole reported income, and operating cash flow was negative ₹94.17 lakh for H1FY27.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Net profit | ₹-0.13 Cr | N/A | |
| EPS | ₹-0.62 | N/A | |
| EBIT margin | N/A |
P&L walk
Standalone net loss narrowed to ₹13.11 lakh from ₹33.62 lakh QoQ as total expenses fell to ₹20.99 lakh from ₹33.62 lakh, while ₹7.88 lakh of other income partly offset the absence of disclosed operating revenue.
Key positives
- Net loss narrowed to ₹13.11 lakh from ₹33.62 lakh QoQ as total expenses declined 37.6% to ₹20.99 lakh.
- Administrative expenses fell to ₹16.09 lakh from ₹31.31 lakh QoQ.
- Property, plant and equipment increased to ₹37.76 lakh from nil, with depreciation of ₹0.72 lakh recorded in the quarter.
Key concerns
- No operating revenue is disclosed, leaving the software/consulting operating model unvalidated in this filing.
- The ₹7.88 lakh of other income, identified as interest income, was the sole reported income and materially supported the result.
- Operating cash flow was negative ₹94.17 lakh for H1FY27 versus negative ₹0.93 lakh in H1FY26, despite the reported narrowing of the quarterly loss.
- Cash and cash equivalents fell to ₹3.55 lakh from ₹75.59 lakh by 30 September 2026.
Research and educational content only. Not investment advice.